TRLS-09. USE OF A PAN-PEPTIDE CHECKPOINT INHIBITOR IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM TUMORS

Abstract

Abstract Immunotherapy has revolutionized clinical management of a select group of malignancies by offering a long-term, durable treatment response. Unfortunately, only a small percentage of brain cancers respond. The combination of multiple checkpoint inhibitors may result in serious immune-related adverse events. We have developed a Pan-Immune Checkpoint Ligand that simultaneously controls multiple immune checkpoints. The CD200 immune checkpoint modulates the immune system through a single inhibitory receptor (CD200R1) and multiple activation receptors (CD200ARs). We developed a peptide ligand, CD200AR-L, that targets the CD200ARs, which results in activation of the immune system and suppression of the inhibitory effects of CD200 and other immune checkpoints. Treatment of high-grade glioma in companion dogs with autologous tumor lysate vaccinations and CD200AR-L resulted in a two-year progression-free survival rate of 20% with no significant adverse events. We believe this response is due to the ability of CD200AR-L to modulate multiple immune checkpoints through shared signaling molecules in both the CD200 and PD-1/PD-L1 checkpoint pathways. Our preliminary data demonstrate that CD200R1 and PD-1 mediated immune checkpoint signaling is through SHIP1. CD200AR-L overcomes the immunosuppressive effects of the tumor-derived CD200 and PD-L1 by downregulating these checkpoints on both antigen-presenting cells (APC) and T-cells. CD200AR-L also downregulates PD-1 on APCs and inhibits the upregulation of PD-1 and CTLA4 on T cells. This translational research has led to the initiation of a phase I dose-escalation clinical trial for recurrent glioblastoma in adults (NCT04642937) and the writing of an IND for a pediatric HGG/DIPG trial.